Form 4 for VRXA Veraxa Biotech AG - Post de-SPAC
Accepted 2026-08-31 16:10:24 ET · period of report 2026-08-27 · accession 0001829126-26-009544 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2026-08-31 16:10 | 2026-08-27 | VRXA | Baumann Oliver Rolf | Dir | P - Purchase | $1.50 | +50.0K | 5.77M | +0.9% | +$75.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2026-08-27 | P | A | 50,000 | $1.50 | 5,773,618 | I See Footnote | — | — | (F1) The reported securities are held by Akira Holding AG. The reporting person may be deemed to beneficially own such securities by virtue of their relationship with Akira Holding AG. (F1) The reported securities are held by Akira Holding AG. The reporting person may be deemed to beneficially own such securities by virtue of their relationship with Akira Holding AG. |